Milton H. Werner

President, Chief Executive Officer and Director

Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.

Affiliation history

Recorded current and former roles; source labels appear when available.

Recorded roles and earnings-call appearances connecting this person to public companies.

IKT

CEO, Board Member

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year	Company	Role	Salary	Bonus	Stock awards	Option awards	Incentive	Other	Total
2025	Inhibikase Therapeutics, Inc. (IKT)	Former President and Chief Executive Officer	$728,979	—	—	$40,449	$31,543	$2,092	$803,063
2024	Inhibikase Therapeutics, Inc. (IKT)	Former President and Chief Executive Officer	$523,004	—	—	$7,174,108	$267,750	$15,761	$7,980,623
2023	Inhibikase Therapeutics, Inc. (IKT)	Former President and Chief Executive Officer	$510,000	—	—	$113,472	$170,850	$17,107	$811,429
2022	Inhibikase Therapeutics, Inc. (IKT)	President and Chief Executive Officer	$500,833	—	—	$85,865	$140,250	$17,107	$744,055
2021	Inhibikase Therapeutics, Inc. (IKT)	President and Chief Executive Officer	$455,000	—	—	—	$138,548	$17,107	$610,655
2020	Inhibikase Therapeutics, Inc. (IKT)	President and Chief Executive Officer	$292,800	—	—	$653,378	—	$14,541	$960,719
2019	Inhibikase Therapeutics, Inc. (IKT)	President and Chief Executive Officer	$292,800	—	—	$77,276	—	$14,541	$384,617

Earnings-call appearances and filed executive appointments or departures, newest first.